
Building A Biotech Hub with Intellia Therapeutics' John Leonard, M.D.
Business Of Biotech
Clinical Pipeline Update and Future Plans
This chapter provides an update on the company's clinical pipeline, including phase three progress of Loydosis for TTRM and plans for hereditary angioedema program. They also discuss plans for expanding technologies to other areas and mention future plans for ophthalmological diseases and allogeneic ex vivo work.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.